Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

1.

Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.

Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL.

AIDS. 2009 Aug 24;23(13):1707-15. doi: 10.1097/QAD.0b013e32832b43f2.

PMID:
19584701
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M.

J Viral Hepat. 2012 Nov;19(11):801-10. doi: 10.1111/j.1365-2893.2012.01601.x. Epub 2012 Mar 15.

PMID:
23043387
[PubMed - indexed for MEDLINE]
3.

Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.

Wongprasit P, Manosuthi W, Kiertiburanakul S, Sungkanuparph S.

AIDS Patient Care STDS. 2010 Apr;24(4):205-9. doi: 10.1089/apc.2009.0322.

PMID:
20377434
[PubMed - indexed for MEDLINE]
4.

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.

Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ.

Hepatology. 2008 Oct;48(4):1062-9. doi: 10.1002/hep.22462.

PMID:
18697216
[PubMed - indexed for MEDLINE]
5.

Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.

Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.

Antivir Ther. 2008;13(3):341-8.

PMID:
18572746
[PubMed - indexed for MEDLINE]
6.

Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.

Alvarez-Uria G, Ratcliffe L, Vilar J.

HIV Med. 2009 May;10(5):269-73. doi: 10.1111/j.1468-1293.2008.00683.x. Epub 2009 Feb 5.

PMID:
19210695
[PubMed - indexed for MEDLINE]
7.

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.

Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J.

HIV Med. 2009 Apr;10(4):229-35. doi: 10.1111/j.1468-1293.2008.00675.x. Epub 2009 Jan 28.

PMID:
19178592
[PubMed - indexed for MEDLINE]
8.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
[PubMed - indexed for MEDLINE]
9.

Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.

Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS, da Silva AC, Guastini CF, Martins LG, Leite AG, Silva MH, Gianini RJ, Uip DE.

BMC Infect Dis. 2011 Sep 20;11:247. doi: 10.1186/1471-2334-11-247.

PMID:
21933423
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.

Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ.

Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.

PMID:
19115219
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.

Núñez M, Ramos B, Díaz-Pollán B, Camino N, Martín-Carbonero L, Barreiro P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):842-8.

PMID:
16989608
[PubMed - indexed for MEDLINE]
12.

High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.

Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE.

J Med Virol. 2010 Sep;82(9):1481-8. doi: 10.1002/jmv.21845.

PMID:
20648600
[PubMed - indexed for MEDLINE]
13.

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.

Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.

J Viral Hepat. 2007 Mar;14(3):176-82.

PMID:
17305883
[PubMed - indexed for MEDLINE]
14.

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.

Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.

AIDS. 2006 Oct 3;20(15):1951-4.

PMID:
16988516
[PubMed - indexed for MEDLINE]
15.

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.

Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J.

AIDS. 2003 Jul 25;17(11):1649-57.

PMID:
12853747
[PubMed - indexed for MEDLINE]
16.

[Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].

Smit MC, Haverkamp MH, Weersink AJ, Boucher CA, Hoepelman IM.

Ned Tijdschr Geneeskd. 2004 Nov 20;148(47):2330-4. Dutch.

PMID:
15587052
[PubMed - indexed for MEDLINE]
17.

HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.

Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.

PMID:
23892239
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.

Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.

AIDS. 2008 Sep 12;22(14):1779-87. doi: 10.1097/QAD.0b013e32830b3ab5.

PMID:
18753861
[PubMed - indexed for MEDLINE]
19.

Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.

Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, Girard PM.

AIDS. 2005 Jun 10;19(9):907-15.

PMID:
15905671
[PubMed - indexed for MEDLINE]
20.

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.

Antivir Ther. 2005;10(6):727-34.

PMID:
16218172
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk